Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen delivered a Q2 beat on the top and bottom lines, but a lack of important disclosures is hurting sentiment for BIIB stock. The post Biogen (BIIB) Stock Dips Following Q2 Earnings Report appeared first on InvestorPlace.

Biogen (BIIB) Stock Dips Following Q2 Earnings Report

Biogen Inc. (NASDAQ:BIIB ) Q2 2022 Results Earnings Conference Call July 20, 2022 8:00 AM ET Company Participants Michael Hencke - Head of IR Michel Vounatsos - CEO Priya Singhal - Interim Head, Research and Development Michael McDonnell - CFO Conference Call Participants Brian Abrahams - RBC Capital Markets Matthew Harrison - Morgan Stanley Colin Bristow - UBS Michael Yee - Jefferies Umer Raffat - Evercore ISI Marc Goodman - SVB Securities Salveen Richter - Goldman Sachs Robyn Karnauskas - Truist Securities Cory Kasimov - JPMorgan Jay Olson - Oppenheimer Philip Nadeau - Cowen and Company Geoff Meacham - Bank of America Evan Seigerman - BMO Capital Markets Operator Good morning. My name is Katie, and I will be your conference operator today.

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2022 Results - Earnings Call Transcript

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

Biogen Inc (NASDAQ: BIIB ) earlier lifted its full-year profit forecast after reporting blowout second-quarter profits of $5.25 per share on revenue of $2.59 billion, both of which came in above Wall Street's expectations, as sales of multiple sclerosis (MS) drug Tecfidera topped estimates.

Biogen Stock Moves Lower Despite Beat-and-Raise

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates

The company said earnings are expected to be between $15.25 and $16.75 per share for this year, more than prior expectation of $14.25 to $16.00.

Biogen Stock Is Falling Despite an Upbeat Outlook. Here's Why.

Shares of Biogen Inc. were down 2.8% in premarket trading on Wednesday after the company missed on revenue in the second quarter of the year. Revenue for three of Biogen's top-selling therapies ⁠- muscular-atrophy therapy Spinraza and multiple-sclerosis drugs Tecfidera and Tysabri ⁠- was lower this quarter than in the same three months of last year.

Biogen's stock is down 2.8% after missing on revenue in the second quarter

Biogen stock fell early Wednesday after the biotech company reported adjusted profit of $5.25 per share on sales $2.59 billion in the second quarter. The post Biogen Stock Falls Despite Beat-And-Raise Q2 Report appeared first on Investor's Business Daily.

Biogen Stock Falls Despite Beat-And-Raise Q2 Report

(Reuters) -Biogen Inc on Wednesday posted second-quarter profit that more than doubled, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture.

Biogen profit more than doubles on Samsung Bioepis stake sale

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years.

Biogen Is Starting To Trend Higher (Technical Analysis)

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Vertex Pharmaceuticals

Regeneron Pharmaceuticals

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.

7 Moonshot Investments Upending a $10 Trillion Industry

The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

Things could get worse before they get better for this drugmaker.

Is This Biotech Stock a Bad News Buy?

The FDA will decide whether to approve lecanemab on the basis of early-stage data showing that it can clear brain plaques.

Alzheimer's Drug Is Up for Accelerated Approval. Outlook for Biogen, Eisai Is Uncertain.

Wilmington, Delaware--(Newsfile Corp. - July 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Biogen Inc. (NASDAQ: BIIB) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-biogen-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biogen Inc.

Illumina

IQVIA Hlds

These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead.

3 Biotech Stocks to Sell Now

BioNTech SE

Gilead Sciences

Halozyme Therapeutics

Moderna

United Therapeutics

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.

7 Biotech Stocks With Key Catalysts Coming in July

Biogen Inc. BIIB, +2.12% said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company updated the study's ClinicalTrials.gov listing with this information on Tuesday.

Biogen stops clinical trial tracking Aduhelm

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment optio

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA ® (dimethyl fumarate). The patent, EP 2 653 873, is directed to treating multiple sclerosis using dimethyl fumarate dosed at 480mg per day, which is the European Medicines Agency (EMA) recommended maintenance dose for TECFIDERA.

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

Duke Realty

FedEx

Monster Beverage

SPDR S&P 500 ETF Trust

The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY?

5 Stocks in S&P 500 ETF That Gained Last Week

Roche Holding AG

Eli Lilly

Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.

Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen

Alnylam Pharmaceuticals

Baxter

Boston Scientific

Cardinal Health

Johnson & Johnson

Karuna Therapeutics Inc

Medtronic

Mirati Therapeutics

Natera

Stryker

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

Karyopharm Therapeutics

Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of.

News for Biogen Stock (BIIB)